These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36787550)

  • 1. Effects of Ruxolitinib on Myeloproliferative Neoplasms via the Negative Regulators.
    Wang SY; Xie XL; Liang JY; Cheng ZY
    Clin Lab; 2023 Feb; 69(2):. PubMed ID: 36787550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Regulation of Ruxolitinib on matrix metalloproteinase in JAK2V617F positive myeloroliferative neoplasms cells].
    Liu GM; Zhang LJ; Fu JZ; Liang WT; Cheng ZY; Bai P; Bian YS; Wan JS
    Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):140-145. PubMed ID: 28279039
    [No Abstract]   [Full Text] [Related]  

  • 3. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.
    de Melo Campos P; Machado-Neto JA; Eide CA; Savage SL; Scopim-Ribeiro R; da Silva Souza Duarte A; Favaro P; Lorand-Metze I; Costa FF; Tognon CE; Druker BJ; Olalla Saad ST; Traina F
    Oncotarget; 2016 Feb; 7(6):6948-59. PubMed ID: 26755644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Ruxolitinib on Immune Checkpoint Molecule Expression in JAK2 V617F-Positive Cells.
    Fu J; Cheng Z; Zhang L; Wen X; Hao J
    Clin Lab; 2024 Oct; 70(10):. PubMed ID: 39382932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of IFN-α2b on COX-2 and Angiogenesis in JAK2V617F Mutation Myeloproliferative Neoplasms].
    Zhao YL; Zhang LJ; Fu JZ; Xu Q; Liu GM; Xie XL; Liang WT; Cheng ZY
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2016 Jul; 47(4):473-478. PubMed ID: 28591945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms.
    Hao X; Xing W; Yuan J; Wang Y; Bai J; Bai J; Zhou Y
    Invest New Drugs; 2020 Jun; 38(3):610-620. PubMed ID: 31227936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.
    Yin LH; Zheng XQ; Li HY; Bi LX; Shi YF; Ye AF; Wu JB; Gao SM
    Leuk Res; 2015 Apr; 39(4):471-8. PubMed ID: 25666256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-angiogenic effect of interferon on JAK2V617F positive myeloproliferative neoplasms and its anti-angiogenic mechanisms].
    Fu J; Xu Q; Zhao Y; Liu G; Cheng Z; Liang W; Xie X; Gu L
    Zhonghua Yi Xue Za Zhi; 2015 Dec; 95(46):3727-32. PubMed ID: 26850010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.
    Rampal R; Al-Shahrour F; Abdel-Wahab O; Patel JP; Brunel JP; Mermel CH; Bass AJ; Pretz J; Ahn J; Hricik T; Kilpivaara O; Wadleigh M; Busque L; Gilliland DG; Golub TR; Ebert BL; Levine RL
    Blood; 2014 May; 123(22):e123-33. PubMed ID: 24740812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.
    Lewandowski K; Kanduła Z; Gniot M; Paczkowska E; Nawrocka PM; Wojtaszewska M; Janowski M; Mariak M; Handschuh L; Kozlowski P
    Ann Hematol; 2022 Dec; 101(12):2665-2677. PubMed ID: 36266510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating CD133+/–CD34– Have Increased c-
    Uslu Bıçak İ; Tokcan B; Yavuz AS; Tokdemir SS
    Turk J Haematol; 2023 Feb; 40(1):28-36. PubMed ID: 36458557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.
    Gurska LM; Okabe R; Schurer A; Tong MM; Soto M; Choi D; Ames K; Glushakow-Smith S; Montoya A; Tein E; Miles LA; Cheng H; Hankey-Giblin P; Levine RL; Goel S; Halmos B; Gritsman K
    Clin Cancer Res; 2023 Mar; 29(5):943-956. PubMed ID: 36537918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylated alteration of SHP1 complements mutation of JAK2 tyrosine kinase in patients with myeloproliferative neoplasm.
    Yang JJ; Chen H; Zheng XQ; Li HY; Wu JB; Tang LY; Gao SM
    Asian Pac J Cancer Prev; 2015; 16(6):2219-25. PubMed ID: 25824741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
    Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
    J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
    Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
    Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
    Bhagwat N; Levine RL; Koppikar P
    Int J Hematol; 2013 Jun; 97(6):695-702. PubMed ID: 23670175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2 V617F-dependent upregulation of PU.1 expression in the peripheral blood of myeloproliferative neoplasm patients.
    Irino T; Uemura M; Yamane H; Umemura S; Utsumi T; Kakazu N; Shirakawa T; Ito M; Suzuki T; Kinoshita K
    PLoS One; 2011; 6(7):e22148. PubMed ID: 21789226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
    Gao SM; Chen CQ; Wang LY; Hong LL; Wu JB; Dong PH; Yu FJ
    Exp Hematol; 2013 Mar; 41(3):261-70.e4. PubMed ID: 23111066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
    Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
    Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.